CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Dallas, Texas, United States and 51 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Dallas, Texas, United States and 9 other locations
The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...
Phase 2, Phase 3
Fort Worth, Texas, United States and 7 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Dallas, Texas, United States and 105 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Dallas, Texas, United States and 23 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Dallas, Texas, United States and 23 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...
Phase 1, Phase 2
Fort Worth, Texas, United States and 11 other locations
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...
Phase 3
Dallas, Texas, United States and 69 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Dallas, Texas, United States and 110 other locations
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...
Phase 3
Dallas, Texas, United States and 222 other locations
Clinical trials
Research sites
Resources
Legal